First author [ref.] | Study | Subjects n | Follow-up | Severity | Mortality |
Schols [92] | Single-centre retrospective cohort | 412 | 48 months | Mean FEV1 39% | FFMI predicts mortality independently of BMI, fat mass, age and sex |
Landbo [93] | CCHS prospective cohort | 2132 | 17 years | Mean FEV1 64–66% | Low BMI (<20 kg·m−2) versus normal BMI (20–25) Male: RR 1.64 (95% CI 1.2–2.23) Female: RR 1.42 |
Chailleux [94] | ANTADIR retrospective cohort | 4088 | 7.5 years (average) | FEV1 630–860 mL LTOT | Low BMI is a risk factor for mortality, independently of age, FEV1, PaO2 and sex |
Soler-Cataluna [95] | Single-centre prospective cohort | 96 | 3 years | Mean FEV1 44% | Anthropometric measurement of muscle depletion ≤25th percentile associated with higher mortality after 12 months (12% versus 5.9%), 24 months (31% versus 7.9%) and 36 months (39.2% versus 13%) |
Vestbo [91] | CCHS prospective cohort | 1898 | 7 years | GOLD 0–IV | Percentage of malnourished subjects is higher in females than males Low BMI increases risk of overall mortality (HR 1.8) and COPD-related mortality (HR 3.2) |
CCHS: Copenhagen City Heart Study; ANTADIR: Observatory of Association Nationale pour le Traitement a Domicile de l'Insuffisance Respiratoire Chronique; FEV1: forced expiratory volume in 1 s; LTOT: long-term oxygen therapy; GOLD: Global Initiative for Chronic Obstructive Lung Disease; FFMI: fat-free mass index; RR: relative risk; PaO2: arterial oxygen tension; HR: hazard ratio; COPD: chronic obstructive pulmonary disease.